In spite of their impressive effects on malignancies, there were still a majority of patients who were not able to benefit from the anti–PD-1/programmed death ligand 1 (PD-L1) monotherapy, and these treatments also induce a variety of immune-related adverse events (irAEs), some of which can be fatal (3–7). Here, PDCD1 is linked to cancer.